Ciraparantag is in clinical development as a reversal agent for various anticoagulants including non-vitamin K oral anticoagulants (NOACs). Ciraparantag was previously shown to reverse the anticoagulant effects of edoxaban and enoxaparin, as measured by whole blood clotting time (WBCT).
Thank you for registering!
You may now view the resource below.
In this eBook, we navigate the landscape of biomarker discovery through genomic profiling, exploring technologies, methods, and applications. We hope this collection of articles creates an appreciation for the wide scope of using sequencing assays for biomarker discovery, drug development, and beyond.
The diagnosis and treatment of human diseases and the development of new drugs increasingly rely on our ability to determine patient genotypes using accurate and sensitive pharmacogenomic tests. Many PCR and next-generation sequencing (NGS) based assay platforms are currently available.
However, the type of DNA sequence variants, the number of targets, and the sensitivity requirements are highly diverse in different studies. Here we describe the design, performance, and regulatory considerations of several assay platforms that are accurate, high throughput, cost-effective and customizable. These platforms provide high-quality pharmacogenomic data ideally suited to meet the needs of individual studies.
What will you learn?
* State-of-the-art pharmacogenomic assay platforms currently available
* How to select the optimal platform and assay design to meet the needs of individual studies
* Performances of several commercial or customized pharmacogenomic tests
* Regulatory considerations for pharmacogenomic studies
Who may this interest?
Researchers in genetic diseases, drug metabolism, and related areas
* Drug developers performing R&D and clinical trials
* Clinicians who treat genetic disorders or provide personalized precision medicine
* Genomic service providers who provide or support pharmacogenomic testing
Speaker: Dr. Peter Zhang, SME, Frontage Laboratories (PA, USA).
Dr. Peter Zhang is a subject matter expert at Frontage Laboratories (PA, USA). He received his PhD in 2003 and spent 12 years in academia as a Professor of Functional Genomics. He has authored or co-authored over 50 peer-reviewed journal articles and book chapters. Dr Zhang has taken on various technical leadership roles in the industry in the past 5 years. He currently supports genomic services at Frontage, including all PCR- and NGS-based assay platforms.
Performing robust exploratory tests upfront can save time and money later on in the process. This infographic outlines the top reasons for why clients are encouraged to consider a comprehensive exploratory toxicology program and how it can provide success in GLP studies.